• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Affimed N.V.

    4/21/22 6:07:04 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFMD alert in real time by email
    SC 13G 1 d313799dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. __)*

     

     

    Affimed N.V.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    N01045108

    (CUSIP number)

    April 18, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. N01045108    13G    Page 2 of 10

     

      1.    

      Names of Reporting Persons

     

      Cooperatieve Gilde Healthcare V U.A.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      The Netherlands

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      8,125,000

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      8,125,000

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,125,000

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.6%

    12.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. N01045108    13G    Page 3 of 10

     

      1.    

      Names of Reporting Persons

     

      Gilde Healthcare V Management B.V.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      The Netherlands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      8,125,000

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      8,125,000

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,125,000

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.6%

    12.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. N01045108    13G    Page 4 of 10

     

      1.    

      Names of Reporting Persons

     

      Gilde Healthcare Holding B.V.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      The Netherlands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      8,125,000

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      8,125,000

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,125,000

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.6%

    12.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. N01045108    13G    Page 5 of 10

     

      1.    

      Names of Reporting Persons

     

      Manapouri B.V. (100% owned by Edwin de Graaf)

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      The Netherlands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      8,125,000

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      8,125,000

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,125,000

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.6%

    12.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. N01045108    13G    Page 6 of 10

     

      1.    

      Names of Reporting Persons

     

      Martemanshurk B.V. (100% owned by Pieter van der Meer)

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      The Netherlands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      8,125,000

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      8,125,000

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,125,000

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.6%

    12.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. N01045108    13G    Page 7 of 10

     

    Item 1(a).

    Name of Issuer:

    Affimed N.V. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    Im Neuenheimer Feld 582, 69120 Heidelberg, Germany

     

    Item 2(a).

    Name of Person Filing:

    Cooperatieve Gilde Healthcare V U.A.

    Gilde Healthcare V Management B.V.

    Gilde Healthcare Holding B.V.

    Manapouri B.V. (100% owned by Edwin de Graaf)

    Martemanshurk B.V. (100% owned by Pieter van der Meer)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    c/o Gilde Healthcare Partners B.V.

    Newtonlaan 91

    3584 BP Utrecht

    The Netherlands

     

    Item 2(c).

    Citizenship:

    Each of the reporting persons is organized and based in the Netherlands.

     

    Item 2(d).

    Title of Class of Securities:

    This Statement refers to the Common Shares of the Issuer.

     

    Item 2(e).

    CUSIP No.:

    N01045108

     

    Item 3.

    If This Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

    Not applicable.

     

    Item 4.

    Ownership

     

      (a)

    Amount beneficially owned:

     

    Cooperatieve Gilde Healthcare V U.A.    8,125,000 shares
    Gilde Healthcare V Management B.V.    8,125,000 shares
    Gilde Healthcare Holding B.V.    8,125,000 shares
    Manapouri B.V. (100% owned by Edwin de Graaf)    8,125,000 shares
    Martemanshurk B.V. (100% owned by Pieter van der Meer)    8,125,000 shares

    8,125,000 shares are held of record by Cooperatieve Gilde Healthcare V U.A. Gilde Healthcare V Management B.V. is the managing director of Cooperatieve Gilde Healthcare V U.A. and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare V Management B.V. is fully owned by Gilde Healthcare Holding B.V., which is also its sole managing director. The managing directors of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Gilde Healthcare V Management B.V. disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.


    CUSIP No. N01045108    13G    Page 8 of 10

     

    Each of Messrs. de Graaf and Manapouri B.V. and van der Meer and Martemanshurk B.V. each disclaim beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

     

      (b)

    Percent of class:

     

    Cooperatieve Gilde Healthcare V U.A.    5.6%
    Gilde Healthcare V Management B.V.    5.6%
    Gilde Healthcare Holding B.V.    5.6%
    Manapouri B.V. (100% owned by Edwin de Graaf)    5.6%
    Martemanshurk B.V. (100% owned by Pieter van der Meer)    5.6%

    These percentages are based on 145,919,772 common shares (“Common Shares”) of Affimed N.V. (the “Issuer”) stated to be outstanding immediately after the offering as reported in the Issuer’s prospectus supplement (Registration No. 333-260946) filed with the Securities and Exchange Commission (“SEC”) pursuant to Rule 424(b)(5) on April 14, 2022.

     

      (c)

    Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote:

     

    Cooperatieve Gilde Healthcare V U.A.    0 shares
    Gilde Healthcare V Management B.V.    0 shares
    Gilde Healthcare Holding B.V.    0 shares

    Manapouri B.V. (100% owned by Edwin de Graaf)

       0 shares
    Martemanshurk B.V. (100% owned by Pieter van der Meer)    0 shares

    (ii) Shared power to vote or to direct the vote:

     

    Cooperatieve Gilde Healthcare V U.A.    8,125,000 shares
    Gilde Healthcare V Management B.V.    8,125,000 shares
    Gilde Healthcare Holding B.V.    8,125,000 shares

    Manapouri B.V. (100% owned by Edwin de Graaf)

       8,125,000 shares
    Martemanshurk B.V. (100% owned by Pieter van der Meer)    8,125,000 shares

    (iii) Sole power to dispose or to direct the disposition of:

     

    Cooperatieve Gilde Healthcare V U.A.    0 shares
    Gilde Healthcare V Management B.V.    0 shares
    Gilde Healthcare Holding B.V.    0 shares

    Manapouri B.V. (100% owned by Edwin de Graaf)

       0 shares
    Martemanshurk B.V. (100% owned by Pieter van der Meer)    0 shares

    (iv) Shared power to dispose or to direct the disposition of:

     

    Cooperatieve Gilde Healthcare V U.A.    8,125,000 shares
    Gilde Healthcare V Management B.V.    8,125,000 shares
    Gilde Healthcare Holding B.V.    8,125,000 shares

    Manapouri B.V. (100% owned by Edwin de Graaf)

       8,125,000 shares
    Martemanshurk B.V. (100% owned by Pieter van der Meer)    8,125,000 shares

     

    Item 5.

    Ownership of 5 Percent or Less of a Class

    Not applicable.


    CUSIP No. N01045108    13G    Page 9 of 10

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    See Item 4(a) above.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certifications

    Not applicable.

    EXHIBIT INDEX

     

    Exhibit
    No.
      

    Description

    Exhibit 1    Joint Filing Agreement, as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.


    CUSIP No. N01045108    13G    Page 10 of 10

     

    Signatures

    After reasonable inquiry and to the best knowledge and belief of the undersigned, such person certifies that the information set forth in this Statement with respect to such person is true, complete and correct.

     

    Dated: April 21, 2022       COOPERATIEVE GILDE HEALTHCARE V U.A.
          By: GILDE HEALTHCARE V MANAGEMENT B.V.
          Its: Managing Director
        By:  

    /s/ Edwin de Graaf

          Name:   Edwin de Graaf
          Title:   Managing Director
          GILDE HEALTHCARE V MANAGEMENT B.V.
        By:  

    /s/ Edwin de Graaf

          Name:   Edwin de Graaf
          Title:   Managing Director
          GILDE HEALTHCARE HOLDING B.V.
        By:  

    /s/ Edwin de Graaf

          Name:   Edwin de Graaf
          Title:   Managing Director
         

    MANAPOURI B.V.

        By:  

    /s/ Edwin de Graaf

          Name:   Edwin de Graaf
          Title:   Managing Director
          MARTEMANSHURK B.V.
        By:  

    /s/ Pieter van der Meer

          Name:   Pieter van der Meer
          Title:   Managing Director
    Get the next $AFMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFMD

    DatePrice TargetRatingAnalyst
    5/14/2025Buy → Neutral
    H.C. Wainwright
    5/13/2025Outperform → Market Perform
    Leerink Partners
    12/12/2022$6.00Buy
    H.C. Wainwright
    10/10/2022$9.00 → $2.00Buy → Hold
    Stifel
    8/18/2022Overweight
    Wells Fargo
    3/31/2022$7.00Overweight
    Piper Sandler
    2/23/2022$12.00Overweight
    Cantor Fitzgerald
    10/21/2021$10.00Buy
    Truist
    More analyst ratings

    $AFMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Affimed Announces Receipt of Nasdaq Delisting Notice

    MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the "Staff") notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company's common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company's securities from The Nasdaq Stock Market ("Nasdaq")

    5/14/25 6:45:00 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Affimed Announces Filing for the Opening of Insolvency Proceedings

    MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the "Company") has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital. Despite its continuous and ongoing fundraising efforts, the Company has not been able to raise sufficient additional funds to continue the operations of the Company and

    5/13/25 8:15:00 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

    An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an ex

    4/29/25 10:00:00 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Affimed Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Affimed Therapeutics from Buy to Neutral

    5/14/25 8:54:15 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Affimed Therapeutics downgraded by Leerink Partners

    Leerink Partners downgraded Affimed Therapeutics from Outperform to Market Perform

    5/13/25 8:52:30 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Affimed Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Affimed Therapeutics with a rating of Buy and set a new price target of $6.00

    12/12/22 7:32:36 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.

    SCHEDULE 13G/A - Affimed N.V. (0001608390) (Subject)

    5/20/25 4:01:22 PM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Affimed N.V.

    6-K - Affimed N.V. (0001608390) (Filer)

    5/14/25 7:16:40 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Affimed N.V.

    6-K - Affimed N.V. (0001608390) (Filer)

    5/13/25 8:22:43 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    Financials

    Live finance-specific insights

    View All

    Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

    MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/in

    12/9/24 6:30:00 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Affimed Reports Third Quarter 2024 Financial Results & Business Update

    AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a Company conference call on December 17, 2024.Acimtamig (AFM13) combination with AlloNK® (AB-101): Updated clinical data from the four cohorts of the run-in phase to be presented in a poster session at ASH 2024.AFM28 monotherapy phase 1 dose-escalation study: Updated clinical data to be presented at an oral presentation at ASH 2024.Cash runway into Q4 2025: As of September 30, 2024, cash, cash equivalents and investments were €24.1 million. Based on operating and financial plans cash-runway projected

    11/14/24 6:30:00 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

    MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://r

    11/6/24 6:30:00 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    Leadership Updates

    Live Leadership Updates

    View All

    Affimed Appoints Shawn M. Leland as Chief Executive Officer

    MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer (CMO). Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. He has a proven track record in successfully advancing the development of novel oncology assets, rais

    9/3/24 7:45:00 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

    HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort's appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023. "We are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board," said Dr. Thomas Hecht, Chairman of Affimed's Supervisory Board. "Constanze brings a wealth of legal expertise and a deep understanding of the biotech and he

    6/22/23 6:30:00 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

    HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately. The appointment was approved during the Annual General Meeting of Shareholders on June 15, 2021. "We are pleased to welcome Uta to Affimed's Supervisory Board," said Dr. Thomas Hecht, Chairman of the Supervisory Board. "Uta brings unique and very deep and extensive executive experience in the life sciences industry. With over 20 years of leadership roles in driving higher busine

    6/16/21 7:04:39 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Affimed N.V.

    SC 13G - Affimed N.V. (0001608390) (Subject)

    10/24/24 2:49:52 PM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

    SC 13G/A - Affimed N.V. (0001608390) (Subject)

    2/14/24 4:07:21 PM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

    SC 13G/A - Affimed N.V. (0001608390) (Subject)

    2/13/24 1:20:05 PM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care